skip to main content

Cholangiocarcinoma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGI CancersCholangiocarcinomaSCE Medical Oncology

A patient with unresectable intrahepatic cholangiocarcinoma is fit for cisplatin and has no immediately actionable molecular alteration. Which first-line regimen is recommended by NICE TA944?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Durvalumab plus gemcitabine and cisplatin

TA944 recommends durvalumab plus gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary-tract cancer. Ivosidenib and pemigatinib are biomarker- and later-line treatments; the other immunochemotherapy pairings are not the appraised regimen.

Reference: NICE TA944: durvalumab with gemcitabine and cisplatin. https://www.nice.org.uk/guidance/TA944/chapter/1-Recommendations